A Phase 3 interventional study of GWP42003-P and Placebo control in Epilepsy and Lennox Gastaut Syndrome, sponsored by Jazz Pharmaceuticals. Completed at 29 sites in 4 countries. Open to participants aged 2 Years to 55 Years. Per ClinicalTrials.gov, last updated 2022-09-28.
Sponsored by Jazz Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing cannabidiol in Lennox Gastaut Syndrome — 2 open to participants now, 3 under way, none of them phase 3. Cannabidiol · Lennox Gastaut Syndrome.
Among the 13 studies testing cannabidiol in Lennox Gastaut Syndrome, this one is the 2nd largest by enrollment, is one of 3 that started in 2015, is one of 7 in phase 3, and was the 1st registered.
68 studies on the registry are indexed under Lennox Gastaut Syndrome; 13 are open to participants now.
Browse Lennox Gastaut Syndrome studies →2 of the 13 studies testing cannabidiol in Lennox Gastaut Syndrome are open now, in 2 countries. Recruiting first, the newest first:
Elizabeth Donner · Sites in Canada
Ages 2–18
Jazz Pharmaceuticals · Sites in United States
Ages 18+
By country, each count listing its studies:
Cannabidiol: first FDA approval 2018 (EPIDIOLEX), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 4 Lennox Gastaut Syndrome studies recruiting now, none set no upper age limit and 4 stop at 75 or younger; 3 take children under 18; none take healthy volunteers.
This study: 2 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 1 · Phase 3 7 · Phase 4 4
First in 2015; this study’s year is marked. 3 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 225 is above the median of 40 across 49 interventional studies indexed under Lennox Gastaut Syndrome.
Median enrollment 40 across the 13 interventional studies. Of the 7 that completed or were terminated, 6 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 13 have an industry lead sponsor. The 7 most frequent:
Jazz Pharmaceuticals is the lead sponsor of 173 studies on the registry; 18 are open to participants now.
Of its 42 completed or terminated interventional studies of FDA-regulated products, 32 (76%) have results posted.
Jazz Pharmaceuticals has 8 studies filed under Lennox Gastaut Syndrome — fewer than ten, so there is no comparison to draw.
1 of the studies testing cannabidiol in Lennox Gastaut Syndrome that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05044819Jazz PharmaceuticalsAssessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution | 2027-08-01 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies testing cannabidiol in Lennox Gastaut Syndrome, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study was to evaluate the efficacy of GWP42003-P as adjunctive treatment in reducing the number of drop seizures when compared with placebo in participants with Lennox-Gastaut syndrome (LGS).
This study was a 1:1:1 randomized, double-blind, 14-week comparison of 2 dose levels (10 milligram [mg] per kilogram [kg] per day [mg/kg/day] and 20 mg/kg/day) of GWP42003-P versus placebo. Participants who satisfied all inclusion and none of the exclusion criteria began a 28-day baseline observation period. The treatment period consisted of a 2-week titration period followed by a 12-week maintenance period. The 20 mg/kg/day dose was recommended by the Data Safety Monitoring Committee (DSMC) after assessment of safety and pharmacokinetic data from Part A of study GWEP1332 (NCT02091206). The 10 mg/kg/day dose was defined as 50% of the 20 mg/kg/day dose. The first participant was not enrolled into this study until the DSMC had reviewed the safety data from Part A of study GWEP1332.
Participants who satisfied all eligibility criteria were randomized at Day 1 to receive 10 mg/kg/day GWP42003-P, 20 mg/kg/day GWP42003-P, or placebo at a 1:1:1 ratio. Participants in the placebo group were split into 2 equivalent cohorts; one half received 10 mg/kg/day dosing volumes and one half received 20 mg/kg/day dosing volumes. The 2 placebo cohorts were pooled for the analyses of efficacy. Participants titrated GWP42003-P to the 10 mg/kg/day or 20 mg/kg/day (or equivalent volume of placebo) dose over 7 and 11 days, respectively, and remained at this dose for the 12-week maintenance period. Following the end of treatment (Day 99), participants were invited to continue to receive GWP42003-P in an open-label extension (OLE) study under a separate protocol (GWEP1415; NCT02224573). All participants who did not immediately enter the OLE study tapered investigational medicinal product (IMP) (10% per day over 10 days). However, the taper period could be interrupted if the participant wished to enter the OLE study within a 7-day timeframe. Participants who down-titrated IMP returned for an end of taper period visit (Day 109). Participants who did not enter the OLE study or who withdrew prematurely had a safety follow-up visit 28 days later (Day 137).
68 studies on the registry are indexed under Lennox Gastaut Syndrome; 13 are open to participants now.
This study's enrollment of 225 is above the median of 40 across 49 interventional studies indexed under Lennox Gastaut Syndrome.
Browse Lennox Gastaut Syndrome studies →Jazz Pharmaceuticals is the lead sponsor of 173 studies on the registry; 18 are open to participants now.
Of its 42 completed or terminated interventional studies of FDA-regulated products, 32 (76%) have results posted.
Compared within Lennox Gastaut Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Epilepsy. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received GWP42003-P 20 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 20 mg/kg/day over 11 days and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day) period.
Drug: GWP42003-P
Participants received GWP42003-P 10 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 10 mg/kg/day over 7 days and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day) period.
Drug: GWP42003-P
Participants received placebo (0 mg/mL CBD) volume matched to 1 of the 2 dose levels (10 or 20 mg/kg/day) administered orally, half in the morning and half in the evening. To maintain the blinded aspect of the study, participants titrated the placebo dose over 7 to 11 days according to the matched IMP group (7 or 11 days for the 10 or 20 mg/kg/day GWP42003-P groups, respectively) and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day of the matched dose) period.
Drug: Placebo control
GWP42003-P was presented as an oral solution containing 100 mg/milliliter (mL) cannabidiol (CBD) in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants were randomly assigned to receive either 10 or 20 mg/kg/day.
Also known as: Cannabidiol, Epidiolex
Placebo was presented as an oral solution containing 0 mg/mL CBD in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
Also known as: Placebo
Percentage Change From Baseline In Drop Seizure Frequency During The Treatment Period
Drop seizures were recorded by the participant or caregiver using an interactive voice response system (IVRS) diary. Drop seizures were defined as the subset of tonic-clonic, tonic or atonic seizures that were reported as drop seizures in the IVRS. Percentage change from baseline was calculated as: (\[frequency during the treatment period - frequency during baseline\]/frequency during baseline) x 100. The frequency during each period was based on 28-day averages and calculated as: (number of seizures in the period/number of reported days in the IVRS period) x 28. Baseline included all available data prior to Day 1 (28-day average). Negative percentages show an improvement from baseline.
Time frame: Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)
Number Of Participants With A ≥50% Reduction From Baseline In Drop Seizure Frequency During The Treatment Period
Drop seizures were recorded by the participant or caregiver using an IVRS diary. Drop seizures included the subset of tonic-clonic, tonic, or atonic seizures that were reported as drop seizures in IVRS. Percentage change from baseline was calculated as per the primary outcome measure.
Time frame: Baseline to EOT (Day 99) or ET
Percentage Change From Baseline In Total Seizure Frequency During The Treatment Period
Total seizures included the sum of all seizures (tonic-clonic, tonic, atonic, clonic, myoclonic, countable partial, other partial, and absence seizures) recorded by the participant or caregiver using an IVRS diary. Percentage change from baseline was calculated as per the primary outcome measure. Negative percentages show an improvement from baseline.
Time frame: Baseline to EOT (Day 99) or ET
Subject/Caregiver Global Impression Of Change (S/CGIC) Assessment
The S/CGIC was used to assess the participant's overall condition on a 7-point scale, using the markers "very much improved, much improved, slightly improved, no change, slightly worse, much worse, or very much worse" (1 = very much improved; 7 = very much worse). On Day 1 (prior to starting IMP), the caregiver was asked to write a brief description of the participant's overall condition as a memory aid for the S/CGIC questionnaire at subsequent visits. If both a CGIC and SGIC were completed then the CGIC was used; if only a CGIC was completed then the CGIC was used; if only a SGIC was completed then the SGIC was used. Last visit for endpoints assessed at clinic visits was defined as the last scheduled visit (not including the end of taper or safety follow-up visits) at which participant's last evaluation was performed.
Time frame: Baseline to Last Visit (Day 99) or ET
| Milestone | GWP42003-P 20 mg/kg/Day Dose | GWP42003-P 10 mg/kg/Day Dose | Placebo |
|---|---|---|---|
| Started | 76 | 73 | 76 |
| Safety analysis set | 82 | 67 | 76 |
| Intent to treat (itt) analysis set | 76 | 73 | 76 |
| Completed | 67 | 71 | 74 |
| Not completed | 9 | 2 | 2 |
| Withdrew: Protocol deviation | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 0 | 1 |
| Withdrew: Met withdrawal criteria | 1 | 0 | 0 |
| Withdrew: Adverse event | 4 | 1 | 1 |
| Withdrew: Withdrawn by investigator | 1 | 1 | 0 |
Drop seizures were recorded by the participant or caregiver using an interactive voice response system (IVRS) diary. Drop seizures were defined as the subset of tonic-clonic, tonic or atonic seizures that were reported as drop seizures in the IVRS. Percentage change from baseline was calculated as: (\[frequency during the treatment period - frequency during baseline\]/frequency during baseline) x 100. The frequency during each period was based on 28-day averages and calculated as: (number of seizures in the period/number of reported days in the IVRS period) x 28. Baseline included all available data prior to Day 1 (28-day average). Negative percentages show an improvement from baseline.
| percentage change | GWP42003-P 20 mg/kg/Day Dose | GWP42003-P 10 mg/kg/Day Dose | Placebo |
|---|---|---|---|
| Percentage Change From Baseline In Drop Seizure Frequency During The Treatment Period | -41.86 (-72.4 to -1.3) | -37.16 (-63.8 to -5.6) | -17.17 (-37.1 to 0.9) |
Drop seizures were recorded by the participant or caregiver using an IVRS diary. Drop seizures included the subset of tonic-clonic, tonic, or atonic seizures that were reported as drop seizures in IVRS. Percentage change from baseline was calculated as per the primary outcome measure.
| Participants | GWP42003-P 20 mg/kg/Day Dose | GWP42003-P 10 mg/kg/Day Dose | Placebo |
|---|---|---|---|
| Number Of Participants With A ≥50% Reduction From Baseline In Drop Seizure Frequency During The Treatment Period | 30 | 26 | 11 |
Total seizures included the sum of all seizures (tonic-clonic, tonic, atonic, clonic, myoclonic, countable partial, other partial, and absence seizures) recorded by the participant or caregiver using an IVRS diary. Percentage change from baseline was calculated as per the primary outcome measure. Negative percentages show an improvement from baseline.
| percentage change | GWP42003-P 20 mg/kg/Day Dose | GWP42003-P 10 mg/kg/Day Dose | Placebo |
|---|---|---|---|
| Percentage Change From Baseline In Total Seizure Frequency During The Treatment Period | -38.40 (-64.6 to -0.7) | -36.44 (-64.5 to -10.8) | -18.47 (-39.0 to 0.5) |
The S/CGIC was used to assess the participant's overall condition on a 7-point scale, using the markers "very much improved, much improved, slightly improved, no change, slightly worse, much worse, or very much worse" (1 = very much improved; 7 = very much worse). On Day 1 (prior to starting IMP), the caregiver was asked to write a brief description of the participant's overall condition as a memory aid for the S/CGIC questionnaire at subsequent visits. If both a CGIC and SGIC were completed then the CGIC was used; if only a CGIC was completed then the CGIC was used; if only a SGIC was completed then the SGIC was used. Last visit for endpoints assessed at clinic visits was defined as the last scheduled visit (not including the end of taper or safety follow-up visits) at which participant's last evaluation was performed.
| Participants | GWP42003-P 20 mg/kg/Day Dose | GWP42003-P 10 mg/kg/Day Dose | Placebo |
|---|---|---|---|
| Very Much Improved | 6 | 9 | 1 |
| Much Improved | 15 | 14 | 8 |
| Slightly Improved | 22 | 25 | 24 |
| No Change | 25 | 21 | 35 |
| Slightly Worse | 6 | 3 | 4 |
| Much Worse | 1 | 1 | 3 |
| Very Much Worse | 0 | 0 | 0 |
Collected over Day 1 through Day 137 (Safety Follow-up). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GWP42003-P 20 mg/kg/Day Dose-Safety Analysis Set | — | 13/82 (15.9%) | 63/82 (76.8%) |
| GWP42003-P 10 mg/kg/Day Dose-Safety Analysis Set | — | 13/67 (19.4%) | 36/67 (53.7%) |
| Placebo-Safety Analysis Set | — | 8/76 (10.5%) | 40/76 (52.6%) |
| Event | GWP42003-P 20 mg/kg/Day Dose-Safety Analysis Set | GWP42003-P 10 mg/kg/Day Dose-Safety Analysis Set | Placebo-Safety Analysis Set |
|---|---|---|---|
| Status epilepticusNervous system disorders | 4/82 | 7/67 | 3/76 |
| PneumoniaInfections and infestations | 2/82 | 3/67 | 0/76 |
| ConvulsionNervous system disorders | 2/82 | 0/67 | 0/76 |
| PancreatitisGastrointestinal disorders | 0/82 | 1/67 | 0/76 |
| Cholecystitis chronicHepatobiliary disorders | 0/82 | 1/67 | 0/76 |
| Pneumonia bacterialInfections and infestations | 0/82 | 1/67 | 0/76 |
| Pneumonia respiratory syncytial viralInfections and infestations | 0/82 | 1/67 | 0/76 |
| Aspartate aminotransferase increasedInvestigations | 1/82 | 1/67 | 0/76 |
| Transaminases increasedInvestigations | 0/82 | 1/67 | 0/76 |
| DehydrationMetabolism and nutrition disorders | 0/82 | 1/67 | 0/76 |
| Event | GWP42003-P 20 mg/kg/Day Dose-Safety Analysis Set | GWP42003-P 10 mg/kg/Day Dose-Safety Analysis Set | Placebo-Safety Analysis Set |
|---|---|---|---|
| SomnolenceNervous system disorders | 25/82 | 14/67 | 4/76 |
| Decreased appetiteMetabolism and nutrition disorders | 21/82 | 11/67 | 6/76 |
| Upper respiratory tract infectionInfections and infestations | 10/82 | 11/67 | 11/76 |
| PyrexiaGeneral disorders | 9/82 | 6/67 | 12/76 |
| DiarrhoeaGastrointestinal disorders | 12/82 | 7/67 | 6/76 |
| VomitingGastrointestinal disorders | 10/82 | 4/67 | 9/76 |
| NasopharyngitisInfections and infestations | 9/82 | 3/67 | 5/76 |
| FatigueGeneral disorders | 8/82 | 5/67 | 2/76 |
| ConvulsionNervous system disorders | 5/82 | 2/67 | 7/76 |
| IrritabilityPsychiatric disorders | 4/82 | 6/67 | 2/76 |
ITT Analysis Set: Received at least 1 dose of IMP with at least 1 post-baseline efficacy endpoint measurement. Participants were analyzed according to the treatment group to which they were randomized.
| Age, Continuous(years) | GWP42003-P 20 mg/kg/Day Dose-ITT Analysis Set | GWP42003-P 10 mg/kg/Day Dose-ITT Analysis Set | Placebo-ITT Analysis Set | Total |
|---|---|---|---|---|
| Mean | 16.0 ± 10.8 | 15.4 ± 9.5 | 15.3 ± 9.3 | 15.6 ± 9.8 |
| Sex: Female, Male(Participants) | GWP42003-P 20 mg/kg/Day Dose-ITT Analysis Set | GWP42003-P 10 mg/kg/Day Dose-ITT Analysis Set | Placebo-ITT Analysis Set | Total |
|---|---|---|---|---|
| Female | 31 | 33 | 32 | 96 |
| Male | 45 | 40 | 44 | 129 |
Ran from Jun 2015 to primary completion in May 2016, 11 months.
Results were first posted in Jul 2018, 2 years 2 months after primary completion. A results delay was requested in Sep 2017.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cannabidiol